POSIMIR ® (bupivacaine solution) for infiltration use reduced mean pain over 72 hours after arthroscopic subacromial decompression surgery compared with vehicle control and improved several measures ...
Please provide your email address to receive an email when new articles are posted on . Subacromial decompression with arthroscopic rotator cuff repair yielded a 21% risk reduction for revision ...
CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved POSIMIR® (bupivacaine solution) for ...
Please provide your email address to receive an email when new articles are posted on . Durect Corporation has announced the FDA approval of Posimir, a post-surgical, non-opioid local analgesic for ...
Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered directly into the surgical site. Posimir ® (bupivacaine solution) is now available for ...
Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered directly into the surgical site. The Food and Drug Administration (FDA) has approved Posimir ® ...
Arthroscopic subacromial decompression surgery does not reduce pain any more than arthroscopy alone in people with shoulder impingement, researchers say. "[T]he findings from our study suggest that ...
The revision of CPT 29826 from a standalone code to an add-on code — +29826 (Arthroscopy, shoulder, surgical; decompression of subacromial space with partial acromioplasty, with coracoacromial ...
The trial, published in the latest edition of the BMJ, compared outcomes over 10 years in three groups of patients with shoulder pain: those who were offered exercise, those who underwent arthroscopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback